Some Postmenopausal Women From Breast Cancer Can Protect Hormonal Therapy

Some Postmenopausal Women From Breast Cancer Can Protect Hormonal Therapy.
In a declaration that seems to chip the prevailing wisdom that any form of hormone replacement remedial programme raises the risk of breast cancer, a new look at some old data suggests that estrogen-only hormone analysis might protect a small subset of postmenopausal women against the disease. "Exogenous estrogen such as hormone psychotherapy is actually protective" in women who have a low risk for developing mamma tumors, said study author Dr Joseph Ragaz, a medical oncologist and clinical professor in the School of Population & Public Health at the University of British Columbia in Vancouver. With his colleagues, Ragaz took another appearance at matter from the Women's Health Initiative (WHI) study, a resident trial that has focused on ways to prevent breast and colorectal cancer, as well as nature disease and fracture risk, in postmenopausal women.

The team planned to present its findings Thursday at the San Antonio Breast Cancer Symposium in Texas. Research presented at medical meetings is not analyzed by appearance experts, far studies that appear in peer-reviewed medical journals, and all such findings should be considered preliminary. Launched in 1991, the WHI includes more than 161000 US women between the ages of 50 and 79.

Two groups were interest of the venture - women who had had hysterectomies and took estrogen unsurpassed as hormone replacement therapy and a group that took estrogen plus progestin hormone replacement therapy. The claque therapy trial was halted in 2002 after it became clear those women were at increased peril for heart disease and breast cancer.

In the new look at the estrogen-only group "we looked at women who did not have high-risk features". They found that women with no erstwhile history of benign knocker disease had a 43 percent reduction breast cancer risk on estrogen; women with no ancestors history with a first-degree relative with breast cancer had a 32 percent risk reduction and women without early hormone use had a 32 percent reduced risk.

Overall, the 10000-plus participants had a 20 percent reduction in tit cancer risk, a reduction that approached statistical significance. After their review, Ragaz said they concluded that using estrogen alone, extremely if begun in women less than 60 who don't have a uterus, can inform reduce breast cancer risk.

The new review did not receive stimulant company funding. "Women without a uterus should be totally safe and benefit a great deal with estrogen-only use ". Yet, more investigation is needed to find the best treatment regimen, decide who are the ideal candidates and to figure out surely why the estrogen only reduces risk in some women.

The findings don't actually include anything new, said Dr Rowan Chlebowski, a WHI investigator who is ranking of medical oncology/hematology at the Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center. The same results were published back in 2006, when the WHI investigators reported on the estrogen-only arm of the study. "These results have been around for a big patch of time". But, he added that "you have to be wary about interpreting subgroups".

To say estrogen is careful is a little strong. The overall reduction in breast cancer risk found among the 10000 participants - 20 percent - didn't rise to significance from a statistical matter of view. When looked at by subgroups - those with no previous benign breast disease, those with no whilom HRT use, those with no first-degree relative with breast cancer - the reductions were significant growth. "The note is pretty much unchanged by this new review ," he said, adding "I estimate it will get people to look at the data again".